260 related articles for article (PubMed ID: 25739911)
1. Targeted lung denervation for moderate to severe COPD: a pilot study.
Slebos DJ; Klooster K; Koegelenberg CF; Theron J; Styen D; Valipour A; Mayse M; Bolliger CT
Thorax; 2015 May; 70(5):411-9. PubMed ID: 25739911
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of bilateral targeted lung denervation in patients with COPD.
Valipour A; Asadi S; Pison C; Jondot M; Kessler R; Benneddif K; Deslee G; Verdier M; Slebos DJ; Mayse M
Int J Chron Obstruct Pulmon Dis; 2018; 13():2163-2172. PubMed ID: 30038492
[TBL] [Abstract][Full Text] [Related]
3. Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes.
Pison C; Shah PL; Slebos DJ; Ninane V; Janssens W; Perez T; Kessler R; Deslee G; Garner JL; Hartman JE; Degano B; Mayr A; Mayse M; Peterson AD; Valipour A
Respir Res; 2021 Feb; 22(1):62. PubMed ID: 33608007
[TBL] [Abstract][Full Text] [Related]
4. Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients.
Valipour A; Shah PL; Pison C; Ninane V; Janssens W; Perez T; Kessler R; Deslee G; Garner J; Abele C; Hartman JE; Slebos DJ;
Respiration; 2019; 98(4):329-339. PubMed ID: 31220851
[TBL] [Abstract][Full Text] [Related]
5. Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial.
Slebos DJ; Shah PL; Herth FJF; Pison C; Schumann C; Hübner RH; Bonta PI; Kessler R; Gesierich W; Darwiche K; Lamprecht B; Perez T; Skowasch D; Deslee G; Marceau A; Sciurba FC; Gosens R; Hartman JE; Srikanthan K; Duller M; Valipour A;
Am J Respir Crit Care Med; 2019 Dec; 200(12):1477-1486. PubMed ID: 31404499
[No Abstract] [Full Text] [Related]
6. Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3).
Slebos DJ; Degano B; Valipour A; Shah PL; Deslée G; Sciurba FC;
BMC Pulm Med; 2020 Feb; 20(1):41. PubMed ID: 32054473
[TBL] [Abstract][Full Text] [Related]
7. Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2.
Valipour A; Shah PL; Herth FJ; Pison C; Schumann C; Hübner RH; Bonta PI; Kessler R; Gesierich W; Darwiche K; Lamprecht B; Perez T; Skowasch D; Deslee G; Marceau A; Sciurba FC; Gosens R; Hartman JE; Conway F; Duller M; Mayse M; Norman HS; Slebos DJ;
Int J Chron Obstruct Pulmon Dis; 2020; 15():2807-2816. PubMed ID: 33177818
[TBL] [Abstract][Full Text] [Related]
8. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
9. Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2.
Conway F; Tonkin J; Valipour A; Pison C; Schumann C; Bonta PI; Kessler R; Gesierich W; Darwiche K; Lamprecht B; Skowasch D; Johnson PJ; Slebos DJ; Shah PL;
Respiration; 2022; 101(11):1069-1074. PubMed ID: 36302345
[TBL] [Abstract][Full Text] [Related]
10. [Bronchoscopic treatments for COPD].
Mineshita M; Inoue T; Miyazawa T
Nihon Rinsho; 2016 May; 74(5):807-12. PubMed ID: 27254951
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
12. Fixed-dose combination of three drugs, i.e. LABA/LAMA/ICS for COPD: Results of a real-world study from India.
Salvi S; Deb AK; Agarwal M; Tummuru VR; Kodgule R; Hemalatha VS; Awasthi AK; Suraj KP; Pavitran VK; Mourya SP; Thomas P; Vaidya A; Chhowala S; Gogtay J
Pulm Pharmacol Ther; 2020 Aug; 63():101932. PubMed ID: 32777289
[TBL] [Abstract][Full Text] [Related]
13. Physiologic and histopathologic effects of targeted lung denervation in an animal model.
Hummel JP; Mayse ML; Dimmer S; Johnson PJ
J Appl Physiol (1985); 2019 Jan; 126(1):67-76. PubMed ID: 30359539
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance.
Ambrosino N; Foglio K; Balzano G; Paggiaro PL; Lessi P; Kesten S;
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):771-80. PubMed ID: 19281092
[TBL] [Abstract][Full Text] [Related]
15. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk.
Covelli H; Pek B; Schenkenberger I; Scott-Wilson C; Emmett A; Crim C
Int J Chron Obstruct Pulmon Dis; 2016; 11():1-12. PubMed ID: 26730183
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary rehabilitation for chronic obstructive pulmonary disease.
McCarthy B; Casey D; Devane D; Murphy K; Murphy E; Lacasse Y
Cochrane Database Syst Rev; 2015 Feb; 2015(2):CD003793. PubMed ID: 25705944
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia.
Lee SD; Xie CM; Yunus F; Itoh Y; Ling X; Yu WC; Kiatboonsri S
Respirology; 2016 Jan; 21(1):119-27. PubMed ID: 26394882
[TBL] [Abstract][Full Text] [Related]
19. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Janjua S; Fortescue R; Poole P
Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
